Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

NCT ID: NCT03275103

Last Updated: 2026-02-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 355 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-09-19
• Study Completion Date: 2026-01-07

Brief Summary

This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).

Conditions

Multiple Myeloma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A: Single Step Dose Escalation for Cevostamab

Study drug will be administered intravenously on a 21-day cycle. The step-up dose will be given on Cycle 1 Day 1 and the target dose will be given on C1D8. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.

Group Type: EXPERIMENTAL

Cevostamab

Intervention Type: DRUG

Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Arm B: Double Step Dose Escalation for Cevostamab

In Cycle 1, participants will receive 2 step-up doses and a target dose. The step-up dose will be given on Cycle 1 Day 1 and C1D8. The target dose will be given on C1D15. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.

Group Type: EXPERIMENTAL

Cevostamab

Intervention Type: DRUG

Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Arm C: Single Step Dose Expansion for Cevostamab

The single step dose expansion stage of the study may use the dosing and assessment schedule from the single dose escalation arm in Cycle 1, based on data from Arm A.

Group Type: EXPERIMENTAL

Cevostamab

Intervention Type: DRUG

Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Arm D: Double Step Dose Expansion for Cevostamab

The double step dose expansion stage of the study may use the dosing and assessment schedule from the double step dose escalation arm in Cycle 1, based on data from Arm B.

Group Type: EXPERIMENTAL

Cevostamab

Intervention Type: DRUG

Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Arm E: Expansion Phase for Tocilizumab Pretreatment

All participants will receive a single dose of tocilizumab intravenously. An additional dose of tocilizumab may be instituted as premedication for subsequent Cycle 1 dose(s) of cevostamab and Cycle 1 cevostamab doses for other treatment arms.

Group Type: EXPERIMENTAL

Cevostamab

Intervention Type: DRUG

Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Tocilizumab

Intervention Type: DRUG

Tocilizumab will be administered as premedication during Cycle 1.

Arm F: Single Step Dose Expansion for Cevostamab

The single step dose expansion stage of the study may use the dosing and assessment schedule from the single dose escalation arm in Cycle 1, based on data from Arm A.

Group Type: EXPERIMENTAL

Cevostamab

Intervention Type: DRUG

Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Arm G: Double Step Dose Expansion for Cevostamab

The double step dose expansion stage of the study may use the dosing and assessment schedule from the double step dose escalation arm in Cycle 1, based on data from Arm B.

Group Type: EXPERIMENTAL

Cevostamab

Intervention Type: DRUG

Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Arm H: Triple Step Dose Escalation for Cevostamab

In Cycle 1, participants will receive 3 step-up doses and a target dose. The doses will be given on Cycle 1 Days 1, 2-4, 8, and 9-11. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.

Group Type: EXPERIMENTAL

Cevostamab

Intervention Type: DRUG

Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Arm I: Triple Step Dose Expansion for Cevostamab

The triple step dose expansion stage of the study may use the dosing and assessment schedule from the triple step dose escalation arm in Cycle 1, based on data from Arm H.

Group Type: EXPERIMENTAL

Cevostamab

Intervention Type: DRUG

Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Arm J: Expansion Phase for Tocilizumab Pretreatment

All participants will receive a single dose of tocilizumab intravenously. An additional dose of tocilizumab may be instituted as premedication for subsequent Cycle 1 dose(s) of cevostamab and Cycle 1 cevostamab doses for other treatment arms.

Group Type: EXPERIMENTAL

Cevostamab

Intervention Type: DRUG

Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Tocilizumab

Intervention Type: DRUG

Tocilizumab will be administered as premedication during Cycle 1.

Arm K: Compressed Double Step Dose Expansion for Cevostamab

In Cycle 1, participants will receive 2 step-up doses and a target dose. The doses will be given on Cycle 1 Days 1, 4, and 8. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.

Group Type: EXPERIMENTAL

Cevostamab

Intervention Type: DRUG

Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Interventions

Cevostamab

Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Intervention Type: DRUG

Tocilizumab

Tocilizumab will be administered as premedication during Cycle 1.

Intervention Type: DRUG

Other Intervention Names

BFCR4350A; RO7187797; Actemra/RoActemra

Eligibility Criteria

Inclusion Criteria

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
• Life expectancy of at least 12 weeks
• Participants must have relapsed or refractory (R/R) multiple myeloma (MM) for which no established therapy for MM is appropriate and available or be intolerant to those established therapies
• Adverse events from prior anti-cancer therapy resolved to Grade < or = 1, except any grade alopecia and/or peripheral sensory or motor neuropathy which must have resolved to Grade < or = 2
• Measurable disease defined by laboratory test results
• Female participants of childbearing age must agree to remain abstinent or use reliable contraceptive methods during the treatment period, and at least 5 months after last dose of study drug. Women must refrain from breastfeeding during the same period.
• Male participants must agree to refrain from donating sperm, to abstain or use a condom during the treatment period, and for at least 2 months after the last dose of tocilizumab (if applicable).

Exclusion Criteria

• Inability to comply with protocol-mandated hospitalization and activities restrictions
• Pregnant or breastfeeding, or planning to become pregnant during the study or within 5 months after the last dose of cevostamab or within 3 months after the last dose of of tocilizumab (if applicable)
• Prior use of any monoclonal antibody, radioimmunoconjugate, or antibody-drug conjugate as anti-cancer therapy within 4 weeks before first infusion
• Prior treatment with systemic immunotherapeutic agents within 12 weeks or 5 half-lives of the drug, whichever is shorter, before first infusion
• Prior treatment with chimeric antigen receptor (CAR) T-cell therapy within 12 weeks before first cevostamab infusion
• Known treatment-related, immune-mediated adverse events associated with prior immunotherapeutic agents
• Treatment with radiotherapy, any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to first cevostamab infusion
• Autologous stem cell transplantation (SCT) within 100 days prior to first infusion
• Prior allogeneic SCT or solid organ transplantation
• Absolute plasma cell count exceeding 500/micro L or 5% of the peripheral blood white cells
• History of autoimmune disease or of confirmed progressive multifocal leukoencephalopathy
• Known history of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS)
• History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
• Patients with known history of amyloidosis (e.g., positive Congo Red stain or equivalent in tissue biopsy)
• Patients with lesions in proximity of vital organs that may develop sudden decompensation/deterioration in the setting of a tumor flare
• History of other malignancy that could affect compliance with the protocol or interpretation of results
• Current or past history of central nervous system (CNS) disease, or CNS involvement by MM
• Significant cardiovascular disease that may limit a patient's ability to adequately respond to a CRS event
• Symptomatic active pulmonary disease requiring supplemental oxygen
• Within 14 days prior to first cevostamab infusion: known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics within 4 weeks prior to first infusion
• Positive and quantifiable Epstein-Barr virus (EBV) polymerase chain reaction (PCR) or cytomegalovirus (CMV) PCR prior to first study treatment
• Known or suspected chronic active EBV infection, acute or chronic hepatitis C virus (HCV) infection
• Positive serologic or PCR test results for acute or chronic hepatitis B virus (HBV) infection
• Recent major surgery within 4 weeks prior to first infusion
• Human Immunodeficiency Virus (HIV) positive
• Any episode of active, symptomatic COVID-19 infection, or requiring treatment with IV antivirals for COVID-19 (not including COVID-19 primary prophylaxis) within 14 days, prior to first study treatment
• Administration of a live, attenuated vaccine within 4 weeks before first cevostamab infusion or anticipation that such a live attenuated vaccine will be required during the study
• Received systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents), with the exception of corticosteroid treatment <=10 mg/day prednisone or equivalent within 2 weeks prior to first dose of cevostamab and, if applicable, tocilizumab premedication prior to first dose of cevostamab
• History of illicit drug or alcohol abuse within 12 months prior to screening
• Any medical condition or laboratory test abnormality that precludes the participant's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Genentech, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Trials

Role: STUDY_DIRECTOR

Genentech, Inc.

Locations

University of Alabama at Birmingham

Birmingham, Alabama, United States

Mayo Clinic Hospital - Arizona

Scottsdale, Arizona, United States

City of Hope

Duarte, California, United States

University of Colorado Denver

Aurora, Colorado, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Memorial Sloan Kettering

New York, New York, United States

Mount Sinai Hospital

New York, New York, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Tennessee Oncology - Nashville

Nashville, Tennessee, United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States

Peter MacCallum Cancer Center

East Melbourne, Victoria, Australia

Alfred Hospital

Melbourne, Victoria, Australia

University of Calgary Cumming School of Medicine

Calgary, Alberta, Canada

Princess Margaret Cancer Center

Toronto, Ontario, Canada

Jewish General Hospital

Montreal, Quebec, Canada

Clinica Universidad de Navarra

Pamplona/iruña, Navarre, Spain

Hospital Clinico Universitario de Salamanca

Salamanca, , Spain

Countries

United States; Australia; Canada; Spain

Other Identifiers

2018-001041-13

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

2022-502053-34-00

Identifier Type: OTHER

Identifier Source: secondary_id

GO39775

Identifier Type: -

Identifier Source: org_study_id